Conversations in Drug Development Trends

JULY 9, 2024

Due to this meaningful change, the first-ever GLP-1-Based Therapeutics Summit took place in Philadelphia on May 15-16th, 2024, serving as a platform for industry decision-makers to provide invaluable insights for therapeutic strategies.

Clinical Research 52

Clinical Research Treatment Research Clinical Trials 52

Drug Discovery World

MARCH 15, 2024

Biotechnology company Allyx Therapeutics has reported positive Phase Ib clinical data for its lead compound, ALX-001, a first-in-class, synapse-targeted, disease-modifying oral therapy in development for neurodegenerative diseases. The findings were presented at the AD/PD 2024 Conference in Lisbon.

Disease 130

Disease Trials Small Molecule Pharmacokinetics 130

PPD

NOVEMBER 30, 2023

These shifts are a prelude to further change and progress in the clinical trial landscape in 2024. Overall, new technological approaches applied in these settings show remarkable potential to make trials more robust, promote more reliable data acquisition and keep trials on-time and on-budget. This year, the U.S.

Clinical Trials 98

Clinical Trials Trials Clinical Research Drug Development 98

Drug Discovery World

APRIL 29, 2024

Dr Currien MacDonald, Medical Chair Director at WCG, discusses the challenges and opportunities presented by cannabis research. Research support Support for researching cannabidiol is expanding. More importantly, cannabis research received additional governmental support for continued investigation at the end of 2022 with H.R.8454,

Research 147

Research FDA Drug Development Production 147

Fierce BioTech

MARCH 12, 2024

Listing Image PPD-TF-logo.png Listing Introduction Get the latest FSP trends, strategies, and projections for biopharma and biotech companies as Lori Boyce, Vice President, PPD FSP Solutions, and Mike Lydon, Director, PPD FSP Solutions, share findings from The 2024 FSP Trends Report. On Demand Start Date Thu, 04/11/2024 - 12:00

Clinical Research 52

Clinical Research Drug Development Trials Research 52

H1 Blog

DECEMBER 18, 2023

How will AI impact clinical trials? Here’s a look at our top predictions for 2024: 1. Pharmaceutical companies are on the brink of a tech revolution, and will embrace AI as a means to enhance their operations and research capabilities. Will FDA legislation improve diversity?

Trials 64

Trials Clinical Trials FDA Pharmaceutical Companies 64

Drug Discovery World

JUNE 20, 2024

Deepika Khedekar investigates the use of LLMs in clinical trials and how we can overcome the potential challenges to their wider application. Clinical trials make up a large part of this investment, and yet 95% of them fail 2. A single phase III clinical trial can rack up to 3.56 million data points 5.

Clinical Research 147

Clinical Research Research Clinical Trials Trials 147

Alta Sciences

JULY 22, 2024

WATCH THE VIDEO You may also be interested in these resources: Webpage: CNS Drug Development Solutions Webinars: Inside the Pharmacodynamic Toolbox A Review of the FDA's Psychedelic Clinical Research Guidances Image Social_Media_Webinar_CNS_Active_Compounds_v2_04.jpg jpg Tags Clinical Trials Weight 1

Trials 52

Trials Clinical Trials Clinical Development Clinical Research 52

Perficient: Drug Development

FEBRUARY 1, 2024

The conference will take place on February 11-14, 2024, in Orlando, Florida. The SCOPE (Summit for Clinical Ops Executives) conference is a premier event in the field of clinical operations, providing a comprehensive platform for professionals to explore the latest trends and innovations in clinical research.

Science 59

Science Clinical Research Clinical Trials Trials 59

Vial

FEBRUARY 8, 2024

To advance new therapies, pharmaceutical, biotech, and medical device companies engage contract research organizations (CROs) for their know-how in navigating the complex landscape of drug development and regulatory pathways and to run clinical trials.

Clinical Trials 52

Clinical Trials Trials Clinical Research Research 52

Drug Discovery World

MAY 30, 2024

Dr Pollock is the Chief Investigator of the LEGACY03 clinical trial, a study aiming to investigate lymph nodes and vaccination responses across age groups. RA: Could you tell us about the LEGACY03 trial? The study will recruit 48 participants over two winter seasons in 2023-2024 and 2024-2025.

Vaccine 147

Vaccine Protein Expression Clinical Trials Immune Response 147

Vial

DECEMBER 8, 2023

With technological innovation and scientific research propelling the development of new therapies, anticipation for the future is high. As we look forward to 2024, several groundbreaking therapies are poised to radically change the landscape of ophthalmology, providing hope and improved treatment options for patients with ocular conditions.

Therapies 52

Therapies Clinical Trials Trials Treatment 52

PPD

MARCH 28, 2024

Through the first few months of 2024, the economic landscape is showing signs of returning to a semblance of normalcy, mirroring the pre-COVID era. According to Jeffries Equity Research, funding totals exceeded $15 billion in January and February, marking the best monthly tallies in over a year.

Trials 52

Trials Clinical Trials Drug Development Clinical Research 52

Alta Sciences

APRIL 17, 2024

Planning a First-In-Human Clinical Trial? blussier Wed, 04/17/2024 - 20:52 HTML Unique FIH Solutions for Small and Large Molecules Advancing your molecule to first-in-human (FIH) clinical trials is a major milestone.

Clinical Trials 40

Clinical Trials Trials Small Molecule Clinical Research 40

On Medicine

FEBRUARY 8, 2024

Why is the CHARMER trial important? In previous research by members of the CHARMER team, older people and their carers told us that they would like their medicines reviewed by doctors during their hospital stay. The CHARMER trial aims to i ncorporate proactive deprescribing as a routine aspect of care in Older People’s Medicine wards.

Hospitals 109

Hospitals Doctors Trials Clinical Research 109

PPD

JANUARY 5, 2023

In an industry survey led by PPD, Thermo Fisher Scientific’s clinical research business, rare diseases emerged as a top therapeutic area in drug developers’ pipelines, with 39% of global biotech and biopharma leaders pursuing therapies in the broad rare disease space.

Disease 52

Disease Trials Clinical Trials Clinical Research 52

Conversations in Drug Development Trends

JUNE 21, 2024

The 2024 ASCO Annual Meeting from the American Society of Clinical Oncology is a fantastic platform for clinical researchers to discuss the latest advancements and challenges in oncology research. Check out this webinar on navigating the landscape of oncology clinical trials.

Clinical Trials 64

Clinical Trials Clinical Research Immune Response Therapies 64

PPD

APRIL 30, 2024

31, 2022, the EU Clinical Trial Regulation (EU CTR) 536/2014 became applicable, heralding a new era for clinical trials in the European Union (EU). In addition, the constant evolution of EMA and Clinical Trials Coordination Group (CTCG) guidelines requires constant attention.

Clinical Trials 52

Clinical Trials Regulations Trials Pharmaceutical Companies 52

Alta Sciences

JUNE 21, 2024

Simpler Clinical Development From Day Dot blussier Fri, 06/21/2024 - 19:10 HTML Connecting the Dots With Comprehensive CRO Solutions When you CONNECT THE DOTS, you open a world of possibilities. At Altasciences, we connect the dots, so you don’t have to. Ready for a simpler drug development journey? Contact us today.

Clinical Development 52

Clinical Development Clinical Trials Clinical Research Drug Development 52

Vial

MARCH 1, 2024

Introduction Contract research organizations (CROs) are essential in pharmaceutical research and development (R&D). from 2024 to reach US$129.8 ’s services include supporting life sciences research, analytical solutions, and diagnostics or developing and manufacturing therapeutic interventions. billion by 2029.

Clinical Trials 52

Clinical Trials Clinical Research Laboratories Trials 52

Agency IQ

MARCH 1, 2024

What we expect European regulators to do in March 2024 In this recurring feature, AgencyIQ, through public data and previous analysis, determines what European medicine and device regulators will likely do in the month ahead, including key deadlines, meetings, events, planned regulations, comment periods, and more. and national regulators.

Regulations 40

Regulations Biosimilars Clinical Trials Production 40

PPD

MARCH 26, 2024

The PPD clinical research business of Thermo Fisher Scientific conducts an annual survey of more than 150 leaders at pharmaceutical companies around the globe to assess trends in drug discovery and development, including preferences around outsourcing and functional service provider (FSP) utilization.

Pharmaceutical Companies 98

Pharmaceutical Companies Clinical Research Clinical Development Drug Development 98

Agency IQ

FEBRUARY 2, 2024

What We Expect the FDA to do in February and March 2024 (Updated) In this ongoing feature, AgencyIQ looks at public data to determine what the FDA is likely to do in the months ahead, including key deadlines, meetings, events, planned regulations, comment periods and more.

FDA 40

FDA Science Clinical Trials Regulations 40

Agency IQ

MARCH 1, 2024

What We Expect the FDA to do in March and April 2024 In this ongoing feature, AgencyIQ looks at public data to determine what the FDA is likely to do in the months ahead, including key deadlines, meetings, events, planned regulations, comment periods and more.

FDA 40

FDA Science Clinical Trials Regulations 40

Agency IQ

APRIL 12, 2024

Landscape analysis: A look at the regulation of decentralized trials and what’s coming soon In the past few years, regulators and researchers have shown increased interest in leveraging decentralized trial methods – especially following the pandemic.

Regulations 40

Regulations Trials Science Clinical Trials 40

Conversations in Drug Development Trends

DECEMBER 7, 2023

Amidst a shifting clinical landscape characterized by increasingly complex trial designs and growing patient subpopulations, many contract research organizations (CROs) have adopted a “one-stop-shop” strategic approach. What Differentiates Mid-Size CROs? To learn more about our end-to-end services, contact us today.

Clinical Trials 136

Clinical Trials Clinical Development Trials Pharmaceutical Companies 136

Drug Discovery World

MARCH 5, 2024

In her day-to-day role, she is responsible for the development of UCB’s epilepsy discovery strategy, working with researchers to advance understanding of epilepsies while ensuring candidates for a future clinical treatment pipeline to improve the lives of those living with the condition. SD : There are multiple types of epilepsy.

Disease 147

Disease Treatment Research Pharmaceutical Companies 147

Agency IQ

AUGUST 30, 2024

The meeting, scheduled for October 2024, will seek input and recommendations from the committee on the process for informed consent, “new areas of focus” for informed consent, and recent policy on “key information.” By Laura DiAngelo, MPH | Aug 27, 2024 6:36 PM CDT Quick background: The FDA, HHS and informed consent In the U.S.,

FDA 40

FDA Regulations Clinical Trials Production 40

Alta Sciences

JANUARY 23, 2024

Altasciences Appoints New General Manager, Clinical Operations pmjackson Tue, 01/23/2024 - 19:52 Laval, Québec, Monday, January 29, 2024 — Altasciences announced the appointment of James Brazeal as General Manager, Clinical Operations, at its clinical facility in Kansas City.

Clinical Pharmacology 40

Clinical Pharmacology Clinical Trials Pharmaceuticals Clinical Research 40

The Pharma Data

MARCH 23, 2023

In this landmark Phase 3 trial, patients with uncontrolled COPD achieved clinical outcomes with Dupixent at a magnitude never before seen with a biologic. Detailed efficacy and safety results from this trial will be presented in a future scientific forum. AEs leading to deaths were balanced between the two arms (1.7% placebo, 1.5%

Trials 40

Trials Disease Treatment Therapies 40

Vial

MARCH 27, 2024

The Costs of Working with a CRO Running clinical trials is an integral part of the pharmaceutical industry, crucial to the development and approval of new drugs and treatments. However, because these trials come with a significant financial burden, sponsor companies are constantly seeking ways to optimize their operations.

Clinical Trials 52

Clinical Trials Trials International Compliance 52

Agency IQ

AUGUST 16, 2024

By Amanda Conti | Aug 13, 2024 10:00 PM CDT Regulatory context: Psychedelic regulation and drug development A growing body of evidence suggests that psychedelics may provide clinical benefit for certain purposes, especially mental health conditions. The road to research on psychedelic products is paved with obstacles.

FDA 40

FDA Trials Regulations Therapies 40

Drug Discovery World

APRIL 11, 2024

The Program Committee Chairs commented: “It has been an educational, enlightening, and inspiring week of captivating cancer science and research. As we participate in our closing sessions of the AACR Annual Meeting 2024, let us say what an honour and pleasure it has been to serve as the Program Committee Chairs for this year’s meeting.

Biochemical Assays 130

Biochemical Assays DNA Science Pharmacokinetics 130

LifeSciVC

JULY 11, 2023

The meeting brings together tens of thousands of physicians, scientists, patients, advocates, innovators, and those involved in oncology drug development from around the world in order to explore the latest advances in cancer treatment, clinical trials, and translational and clinical research.

Therapies 66

Therapies Trials Clinical Development Science 66

Advarra

APRIL 25, 2024

The only constant in clinical research is change. Researchers are always innovating, making it a necessity to navigate complex organizational change. Technology continues to advance clinical operations, and organizations must proactively adapt. How can your organization stay on top of it all?

Clinical Trials 52

Clinical Trials Research Clinical Research Trials 52

Conversations in Drug Development Trends

NOVEMBER 27, 2023

In trials, Casgevy was shown to help prevent episodes of debilitating pain, known as vaso-occlusive crises, that often plague patients affected by sickle cell disease. Specializing in end-to-end solutions for adult and pediatric cell and gene therapy programs, our integrated teams are here to support your trial every step of the way.

Treatment 75

Treatment FDA Clinical Trials Therapies 75

The Pharma Data

JUNE 24, 2021

today announced that the first participant has been dosed in TALAPRO-3, a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial. The TALAPRO-3 trial will enroll approximately 550 men with DDR-deficient mCSPC across 285 clinical trial sites in 28 countries. About TALAPRO-3 Trial.

DNA 52

DNA Clinical Trials Trials Biosimilars 52